摘要
目的通过随机分组对照观察探讨马来酸桂哌齐特对颅脑损伤患者的治疗效果。方法100例急性闭合性颅脑损伤患者,分为对照组和用药组,各50例病人。分析对比治疗后对照组和用药组的实验室各项检查指标：血液流变学,TCD检查结果等变化情况。并且对出院后3-6个月随访调查结果进行比较分析。结果治疗后血液流变学检查中,用药组(马来酸桂哌齐特组)各项指标均低于对照组(P＜0．05)。经颅多普勒检测结果显示：用药组的脑血流速度与对照组相比明显减慢(P＜0．05),血管痉挛得到缓解。对比两组出院后随访结果可以看出,用药组的GOS评分、KPS评分及Barthel指数预后明显好于对照组(P＜0．05)。结论初步证明急性颅脑损伤早期应用马来酸桂哌齐特可增加病变区的脑血流,改善微循环,改善颅脑损伤患者的预后。值得推广和进一步研究。
Objective To explore the therapeutic results of kelinao in treating craniocerebral trauma patients through a randomized and controlled group method. Methods 100 cases of acute closed craniocerebral trauma patients were divided into the medication and control groups （50 each ）. Each lab testing parameter for both groups of post-treatment was analyzed and compared. The changes of hemorheology and TCD examinations were noted. Also the survey results of 3-6 month post-discharge follow-ups were compared and analyzed. Results In post-treatment hemorheologic tests, each parameter in the medication group （kelinao） was lower than that in the control group （P 〈 0.05 ）. The results of TCD examinations demonstrated that the cerebral blood flow （CBF） in the medication group was much slower than that in the control group （P 〈 0.05 ）. The vascular spasms were relieved. As seen from comparing the post-treatment follow-up results in both groups, the GOS score, KPS score and Bathel index in the medication group were markedly better than in the control group （ P 〈 0.05 ）. Condusion The authors preliminarily proved that the early application of kelinao for acute craniocerebral trauma could increase the CBF in the affected areas, improve the microcirculation and improve the prognosis in patients with craniocerebral trauma. Kelinao is thus worthy of further promotion and exploration.
出处
《中华神经外科杂志》
CSCD
北大核心
2006年第11期663-665,共3页
Chinese Journal of Neurosurgery
关键词
马来酸桂哌齐特
颅脑损伤
治疗结果
Cinepazide maleate
Cranioeerebral trauma
Treatment outcome
